BioXcel Therapeutics (BTAI) Competitors $1.96 +0.03 (+1.55%) Closing price 07/3/2025 03:58 PM EasternExtended Trading$1.99 +0.03 (+1.53%) As of 07/3/2025 04:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock BTAI vs. ATNM, MURA, ANVS, GRCE, SCLX, MDCX, ITRM, PLUR, STTK, and ABVCShould you be buying BioXcel Therapeutics stock or one of its competitors? The main competitors of BioXcel Therapeutics include Actinium Pharmaceuticals (ATNM), Mural Oncology (MURA), Annovis Bio (ANVS), Grace Therapeutics (GRCE), Scilex (SCLX), Medicus Pharma (MDCX), Iterum Therapeutics (ITRM), Pluri (PLUR), Shattuck Labs (STTK), and ABVC BioPharma (ABVC). These companies are all part of the "pharmaceutical products" industry. BioXcel Therapeutics vs. Its Competitors Actinium Pharmaceuticals Mural Oncology Annovis Bio Grace Therapeutics Scilex Medicus Pharma Iterum Therapeutics Pluri Shattuck Labs ABVC BioPharma BioXcel Therapeutics (NASDAQ:BTAI) and Actinium Pharmaceuticals (NYSE:ATNM) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk. Which has more volatility and risk, BTAI or ATNM? BioXcel Therapeutics has a beta of 0.04, meaning that its share price is 96% less volatile than the S&P 500. Comparatively, Actinium Pharmaceuticals has a beta of -0.32, meaning that its share price is 132% less volatile than the S&P 500. Do analysts recommend BTAI or ATNM? BioXcel Therapeutics presently has a consensus price target of $42.60, suggesting a potential upside of 2,073.47%. Actinium Pharmaceuticals has a consensus price target of $4.00, suggesting a potential upside of 177.78%. Given BioXcel Therapeutics' higher possible upside, equities research analysts clearly believe BioXcel Therapeutics is more favorable than Actinium Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioXcel Therapeutics 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.67Actinium Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 Which has better valuation & earnings, BTAI or ATNM? Actinium Pharmaceuticals has lower revenue, but higher earnings than BioXcel Therapeutics. Actinium Pharmaceuticals is trading at a lower price-to-earnings ratio than BioXcel Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioXcel Therapeutics$2.27M5.23-$59.60M-$13.55-0.14Actinium PharmaceuticalsN/AN/A-$48.82M-$1.47-0.98 Is BTAI or ATNM more profitable? Actinium Pharmaceuticals has a net margin of 0.00% compared to BioXcel Therapeutics' net margin of -2,163.18%. BioXcel Therapeutics' return on equity of 0.00% beat Actinium Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets BioXcel Therapeutics-2,163.18% N/A -83.80% Actinium Pharmaceuticals N/A -100.85%-47.89% Do insiders and institutionals hold more shares of BTAI or ATNM? 30.7% of BioXcel Therapeutics shares are owned by institutional investors. Comparatively, 27.5% of Actinium Pharmaceuticals shares are owned by institutional investors. 21.2% of BioXcel Therapeutics shares are owned by company insiders. Comparatively, 6.0% of Actinium Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the media favor BTAI or ATNM? In the previous week, BioXcel Therapeutics had 6 more articles in the media than Actinium Pharmaceuticals. MarketBeat recorded 8 mentions for BioXcel Therapeutics and 2 mentions for Actinium Pharmaceuticals. Actinium Pharmaceuticals' average media sentiment score of 0.31 beat BioXcel Therapeutics' score of 0.21 indicating that Actinium Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioXcel Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Actinium Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryBioXcel Therapeutics beats Actinium Pharmaceuticals on 9 of the 15 factors compared between the two stocks. Get BioXcel Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BTAI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BTAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BTAI vs. The Competition Export to ExcelMetricBioXcel TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$11.69M$2.91B$5.53B$8.95BDividend YieldN/A2.42%5.38%4.09%P/E Ratio-0.1421.5627.4020.24Price / Sales5.23277.33417.66125.07Price / CashN/A41.9536.6357.47Price / Book-0.077.518.085.67Net Income-$59.60M-$55.05M$3.16B$248.47M7 Day Performance10.73%4.59%2.81%3.29%1 Month Performance28.10%4.86%3.69%5.18%1 Year Performance-88.66%5.82%35.30%21.35% BioXcel Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BTAIBioXcel Therapeutics4.3275 of 5 stars$1.96+1.6%$42.60+2,073.5%-88.7%$11.69M$2.27M-0.1490Gap UpATNMActinium Pharmaceuticals2.5124 of 5 stars$1.40-1.4%$4.00+185.7%N/A$43.67M$81K-1.0130MURAMural Oncology2.8579 of 5 stars$2.47-0.4%$12.00+385.8%-13.7%$42.66MN/A-0.32119News CoverageANVSAnnovis Bio1.6702 of 5 stars$2.18+6.3%$30.25+1,287.6%-70.5%$42.49MN/A-1.013GRCEGrace Therapeutics1.7875 of 5 stars$2.97flat$12.00+304.0%N/A$41.08MN/A-3.34N/ASCLXScilex1.7616 of 5 stars$5.89-2.6%$455.00+7,625.0%-90.5%$40.94M$56.59M-0.2080MDCXMedicus Pharma1.8692 of 5 stars$2.99+3.1%$23.50+686.0%N/A$40.57MN/A-2.58N/AAnalyst ForecastGap UpHigh Trading VolumeITRMIterum Therapeutics1.4537 of 5 stars$1.00-1.5%$9.00+804.5%-15.1%$39.80MN/A-1.0110PLURPluri3.6137 of 5 stars$4.95-2.8%$12.00+142.4%+2.1%$38.76M$330K-0.90150News CoverageInsider TradeGap DownSTTKShattuck Labs2.8881 of 5 stars$0.79-7.3%$7.50+847.2%-77.4%$37.93M$5.72M-0.57100Gap UpABVCABVC BioPharma0.1687 of 5 stars$2.22-14.3%N/A+315.1%$37.70M$510K-17.0830News CoverageHigh Trading Volume Related Companies and Tools Related Companies Actinium Pharmaceuticals Alternatives Mural Oncology Alternatives Annovis Bio Alternatives Grace Therapeutics Alternatives Scilex Alternatives Medicus Pharma Alternatives Iterum Therapeutics Alternatives Pluri Alternatives Shattuck Labs Alternatives ABVC BioPharma Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BTAI) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredGold: Now legal tender in many statesThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | SponsoredTrump's ticking time bombA looming tariff deadline on July 9th could be the spark — but what’s buried inside a recent White House docum...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioXcel Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioXcel Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BTAI Stock Alerts